Head-To-Head Review: Chromadex (CDXC) vs. Pharmacyte Biotech (OTCMKTS:PMCB)

Chromadex (NASDAQ:CDXC) and Pharmacyte Biotech (OTCMKTS:PMCB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares Chromadex and Pharmacyte Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -105.57% -90.20% -67.02%
Pharmacyte Biotech N/A -96.25% -84.93%

Analyst Ratings

This is a summary of current ratings for Chromadex and Pharmacyte Biotech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 2 0 3.00
Pharmacyte Biotech 0 0 0 0 N/A

Chromadex presently has a consensus target price of $7.00, indicating a potential upside of 87.17%. Given Chromadex’s higher possible upside, equities research analysts clearly believe Chromadex is more favorable than Pharmacyte Biotech.

Valuation & Earnings

This table compares Chromadex and Pharmacyte Biotech’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chromadex $31.56 million 6.55 -$33.32 million ($0.61) -6.13
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A

Pharmacyte Biotech has lower revenue, but higher earnings than Chromadex.

Institutional and Insider Ownership

17.3% of Chromadex shares are held by institutional investors. Comparatively, 0.2% of Pharmacyte Biotech shares are held by institutional investors. 10.3% of Chromadex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Chromadex has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.

Summary

Chromadex beats Pharmacyte Biotech on 7 of the 10 factors compared between the two stocks.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People's Republic of China. ChromaDex Corporation is based in Irvine, California.

Pharmacyte Biotech Company Profile

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

Leave a Reply